U.S. Generic Pharmaceuticals posted revenue of $497 million, a drop of 7% over third-quarter 2016, as the drop in the U.S. Generics Base business was partly offset by robust growth in Sterile Injectables. Consequently, the company lowered its guidance. Shares have significantly underperformed the industry in the last six months. LMR Partners LLP bought a new position in Endo International PLC during the 3rd quarter valued at approximately $148,000. ValuEngine raised Endo International PLC from a hold rating to a buy rating in a report on Monday, October 2nd. Equity analyst Goldman Sachs Group, Inc. Finally, BidaskClub raised shares of Endo International PLC from a "sell" rating to a "hold" rating in a research note on Wednesday, July 19th. Finally, Morgan Stanley lowered their price target on Endo International PLC from $12.00 to $8.00 and set an equal weight rating for the company in a report on Thursday, August 10th.
In a report issued on October 30, BMO Capital also reiterated a Hold rating on the stock with a $11 price target. The stock presently has a consensus rating of Hold and a consensus price target of $11.67.
The company declined -3.46% and closed its last trading session at $6.93. The company has a debt-to-equity ratio of 10.78, a quick ratio of 0.86 and a current ratio of 1.08. Endo International PLC has a 52-week low of $5.77 and a 52-week high of $18.63. The company's Relative Strength Index which shows price strength now stands at 46.04.
Endo Int'l Plc (NASDAQ:ENDP) has average revenue estimates of $762.29 Million, compared to low analyst estimates of $704.8 Million and high estimates of $804.36 Million for the current quarter. Previously Endo Int'l Plc (NASDAQ:ENDP) reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.2 with surprise factor of 28.2%. EPS long term mean growth rate estimated by 2 analysts is at -6.3%, whereas, the high and low Long term growth rate estimated at 4 and -16.61.
While having a peek at profitability ratios Endo Int'l Plc (NASDAQ:ENDP) has trailing twelve month gross margin at 37.6%, its trailing twelve month operating margin stands at -99.1% whereas its trailing twelve month net profit margin spots at 0%. The stock closing price is now trading downward to its 50 day moving average with change of -12.79%, escalated to its 20 day moving average with figure of 1.27% and behind its 200 day moving average with value -33.69%.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Thursday, November 9th. If you are viewing this report on another website, it was illegally stolen and reposted in violation of USA and worldwide trademark and copyright law. The correct version of this news story can be viewed at https://weekherald.com/2017/11/14/endo-international-plc-endp-downgraded-by-zacks-investment-research.html.
Cardi B Wants Everyone Wearing Red at Her Wedding
But no matter how successful you are, there will always be haters. "Because every time you hear it, your pussy pops". This comes shortly after Cardi vowed to set a "better example" to her fans. "Stop trying to discredit it".
Several other equities research analysts have also recently weighed in on the company.
Endo International plc on 9/29/2017 reported its EPS as $1.77 with the analysts projecting the EPS of the stock as $1.63. The share last price represents downtick move of -62.80% in value from company's 52-Week high price and shows 20.10% above change in value from its 52-Week low price. The value of the investment in ENDP went from $2,142,000 to $1,508,000 decreasing 29.6% quarter to quarter.
The stock has Return on Assets (ROA) of -38.7 percent. Ubs Asset Management Americas Inc now holds 1,584 shares valued at $13,567,000.
WARNING: "Endo International PLC (ENDP) Price Target Cut to $7.00" was first published by BBNS and is the sole property of of BBNS. A total of 9.92 Million shares exchanged hands during the intra-day trade compared with its average trading volume of 6.66 Million shares, while its relative volume stands at 1.49.
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services.